We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Hutchison China MediTech
ASCO 2020: savo and suru data drives regulatory progressMereo BioPharma
Private placement raises $70m (£56m)Nexstim
€2.3m rights issue is 273% subscribedFutura Medical
Nearing the critical point in Erectile DysfunctionMaxCyte
ASCO poster shows encouraging data for MCY-M11Bonesupport
SEK 378m raised through directed share issueMaxCyte
Enabling cell therapies to progressNexstim
Hitting the right spotScancell
COVID 2nd generation vaccine opportunity is all upsideScancell
Reasons to be cheerful